Rafeeq A. Habeeb
FDA Investigator
ORA Division of Pharmaceutical Quality Operations (Rockville, MD)
Investigation quality and CAPA effectiveness specialist with 63 site inspections — known for escalating to untitled letters and OAI classifications when firms provide inadequate responses to 483 observations.
Inspection Approach
How Rafeeq Inspects
Habeeb's inspection methodology centres on the scientific soundness of investigation conclusions and the genuine effectiveness of corrective actions. While other investigators may focus on specific technical areas, Habeeb evaluates whether the quality system actually works — do firms determine true root causes, and do their CAPAs actually prevent recurrence?
At Catalent Indiana, he documented cat and human hair found in vial stoppers, pest infestations, and unresolved contamination complaints dating back years — systemic failures that pointed to a quality system that was documenting problems without solving them. At Laurus Synthesis, co-investigating with Joseph Piechocki, he identified discrepancies between documented records and actual facility state, leading to an untitled letter directing the firm to ensure data accuracy and integrity.
Habeeb's enforcement pattern is notable for escalation willingness. When 483 responses are inadequate, he pursues untitled letters (Laurus) and OAI classifications (Lupin Unit-2) — sending a clear signal that he expects substantive remediation, not paper responses. His inspection of two Lupin units in Pithampur during the same week (July 2025) demonstrates the thoroughness and efficiency of his multi-site approach.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Catalent Indiana, LLC
- Cat and human hair found in vial stoppers during sterile manufacturing operations
- Pest infestations documented in manufacturing areas
- Unresolved contamination complaints dating back years without adequate investigation
- Aseptic processing validation gaps — later classified OAI under Novo Nordisk ownership
Laurus Synthesis Private Limited
- Investigation adequacy failures — CAPA did not address true root causes
- Discrepancies between documented records and actual facility state
- Data integrity concerns identified across documentation systems
- Untitled letter issued May 2024 directing firm to ensure data accuracy and integrity
Lupin Limited (Unit-2)
- Failure to implement CAPA for OOS microbiological results in Grade A environment
- Product quality review deficiencies across manufacturing records
- Classified as Official Action Indicated (OAI) in October 2025 — 4 observations
Lupin Limited (Unit-3)
- Manufacturing deficiencies at oral solid dosage facility — 3 observations
- Inspected concurrently with Unit-2 during same-week multi-site approach
Q Labs, LLC
- Contract laboratory inspection — testing procedure and quality system observations
Pre-Inspection Preparation
How to Prepare
- 1 Audit ALL investigation records for scientific soundness — Habeeb specifically evaluates whether root cause conclusions are evidence-based, not speculative.
- 2 Verify CAPA effectiveness with data proving recurrence prevention — show that corrective actions actually worked, not just that they were implemented.
- 3 Ensure consistency between validated quality systems (TrackWise, etc.) and external communications — no investigation modifications via email.
- 4 Review OOS/OOT investigation procedures — conclusions like "sample bias" or "equipment glitch" without scientific rationale will be cited.
- 5 Prepare environmental monitoring excursion investigations with documented CAPA implementation and effectiveness verification.
- 6 Ensure data integrity across all laboratory and manufacturing systems — verify audit trails and review incomplete/interrupted data sequences.
- 7 For contract laboratories: ensure all testing procedures are validated and scientifically sound for each product tested.
- 8 Have process validation studies that evaluate inter- and intra-batch variability with defined acceptance criteria.
- 9 Ensure microbiological quality monitoring in Grade A/B areas has clear escalation and CAPA procedures when excursions occur.
- 10 Review all prior 483 responses before his arrival — inadequate responses are a red flag for escalation to untitled letters or OAI.
- 11 Ensure investigation timelines are reasonable and documented — open or aged investigations draw scrutiny.
- 12 For multi-site companies: verify that global quality oversight teams document all interactions within validated systems.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Rafeeq A. Habeeb — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
